Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.
This press release contains forward-looking statements, including
without limitation statements related to the future development and
potential efficacy of our compounds, our partners' decisions under their
respective collaborations with us, our estimated future revenues and
expenses, our estimated future balances of cash, cash equivalents,
short-term and long-term marketable securities, investments held by
Symphony Evolution, Inc. and restricted cash; and other matters discussed
in the "Financial Outlook" section. Words such as "hope," "plan," "may,"
"expect," "potential," "opportunity," "will" and similar expressions are
intended to identify forward-looking statements. These forward-looking
statements are based upon our current plans, assumptions, beliefs and
expectations. Forward-looking statements involve risks and uncertainties.
Our actual results and the timing of events could differ materially from
those anticipated in such forward-lo
|SOURCE Exelixis, Inc.|
Copyright©2008 PR Newswire.
All rights reserved